Technical Analysis for CANF - Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Grade Last Price % Change Price Change
grade F 2.3 -7.26% -0.18
CANF closed down 7.26 percent on Wednesday, August 21, 2019, on 1.67 times normal volume. The bears made the stock sink to a new 52-week low. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
0 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical CANF trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Expansion Breakdown Bearish Swing Setup 0.00%
New 52 Week Low Weakness 0.00%
Below Lower BB Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Oversold Stochastic Weakness -7.26%
MACD Bearish Signal Line Cross Bearish -6.88%
New 52 Week Closing Low Bearish -6.88%
180 Bearish Setup Bearish Swing Setup -6.88%

Older signals for CANF ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Read My Charts!
Configure default chart indicators
Basic chart:
Profile
Can-Fite BioPharma, Ltd., a biotechnology company, develops drugs for the treatment of cancer and autoimmune inflammatory diseases. The company principally develops CF101 that is in Phase III study for the treatment of psoriasis; and has completed Phase II study for the treatment of rheumatoid arthritis and glaucoma, as well as completed Phase III study for the treatment of dry eye and Phase I study for the treatment of uveitis. It also develops CF102, which is in Phase II study for the treatment of hepatocellular carcinoma; and CF602 that has completed pre-clinical trial for the treatment of inflammatory diseases. The company was founded in 2000 and is based in Petach Tikva, Israel.
Medicine Biotechnology Cancer Medical Specialties Immunology Treatment Of Cancer Rheumatoid Arthritis Psoriasis Glaucoma Inflammatory Diseases Arthritis Immunosuppressants Hepatocellular Carcinoma Uveitis Biotie Therapies Treatment Of Inflammatory Diseases Treatment Of Psoriasis
Is CANF a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Aug 21 Plus Therapeutics leads healthcare gainers; TrovaGene leads the losers
Aug 9 Can-Fite And The Activist Investor: A Potential Hostile Takeover And Rescue
Aug 8 The Daily Biotech Pulse: Glaukos To Buy Avedro, Mixed Adcom Vote For Gilead, Dynavax Offering
Aug 6 Can-Fite to supply Namodensoson in Israel under compassionate use; shares up 6% premarket
Aug 6 Can-Fite to Treat Advanced Liver Cancer Patients with Namodenoson Under Compassionate Use Setting in Israel
Aug 1 Can-Fite BioPharma Reports $4M Deal With Kyongbo Pharm
Aug 1 SPWR, TRXC among premarket gainers
Jul 31 DelMar Pharmaceuticals leads healthcare gainers; Lexicon Pharmaceuticals and T2 Biosystems among losers
Jul 10 Can-Fite BioPharma Appeals Lawsuit Against Venture Capital Firm
Jun 20 All You Need to Know About Can-Fite (CANF) Rating Upgrade to Strong Buy
See more CANF news...
Indicators
Indicator Value
52 Week High 25.95
52 Week Low 2.15
Average Volume 93,081
200-Day Moving Average 11.3658
50-Day Moving Average 2.8412
20-Day Moving Average 2.6499
10-Day Moving Average 2.5437
Average True Range 0.2119
ADX 16.96
+DI 16.1082
-DI 28.4938
Chandelier Exit (Long, 3 ATRs ) 2.8143
Chandelier Exit (Short, 3 ATRs ) 2.7857
Upper Bollinger Band 2.9795
Lower Bollinger Band 2.3203
Percent B (%b) -0.03
BandWidth 24.87641
MACD Line -0.1584
MACD Signal Line -0.1481
MACD Histogram -0.0103
Fundamentals Value
Market Cap 39.93 Million
Num Shares 17.4 Million
EPS -0.51
Price-to-Earnings (P/E) Ratio -4.51
Price-to-Sales 132.22
Price-to-Book 7.13
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.81
Resistance 3 (R3) 2.82 2.65 2.73
Resistance 2 (R2) 2.65 2.52 2.65 2.70
Resistance 1 (R1) 2.48 2.44 2.40 2.47 2.67
Pivot Point 2.31 2.31 2.27 2.31 2.31
Support 1 (S1) 2.14 2.18 2.06 2.13 1.93
Support 2 (S2) 1.97 2.10 1.97 1.90
Support 3 (S3) 1.80 1.97 1.88
Support 4 (S4) 1.79